Table 2 Patient and disease characteristics

From: A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Characteristics

Arm A

Arm B

Arm C

Arm D

Number of patients

41

37

46

44

Male/female

23/18

17/20

27/19

22/22

Median age (range)

60 (28–75)

58 (41–71)

62 (35–74)

60 (31–76)

 

Percentage of patients

  

WHO performance status

 

 0

29

35

46

34

 1

68

54

52

64

 2

2

11

2

2

Prior therapy

    

 Surgery

100

97

96

100

 Radiotherapy

29

19

24

14

 Chemotherapy

2

14

7

9

Primary tumour site

    

 Colon

54

65

59

71

 Rectum

46

35

41

30

Number of involved organs

 

 1

71

54

65

73

 2

12

41

26

21

3

17

5

9

7

Involved organs

 

 Liver

85

84

72

68

 Lung

27

27

30

11

 Lymph nodes

15

24

22

25

 Soft tissue

5

0

9

18

 Other

22

16

17

14